



RaQualia Pharma Inc.
May 13, 2024

FIMECS Achieved an Initial Milestone in Joint Research with Astellas Pharma Inc. to Receive a Lump-sum Payment

Nagoya, Japan, May 13, 2024 – RaQualia Pharma Inc. (headquartered in Nagoya; President & CEO: Hirobumi Takeuchi, “RaQualia”) is pleased to announce today that FIMECS, Inc. (headquartered in Fujisawa, Japan, “FIMECS”), a consolidated subsidiary of RaQualia, has achieved an initial milestone in a joint research project with Astellas Pharma Inc. (“Astellas”). With the achievement of this milestone, FIMECS will receive a lump-sum payment from Astellas.

FIMECS and Astellas entered into an agreement (“Agreement”) in 2022 to conduct joint research on targeted protein degradation. Since then, under the terms of the Agreement, FIMECS has been collaborating with Astellas to discover protein degraders for multiple targets related to oncology, using FIMECS’s proprietary platform, RaPPIDS™, and now has achieved an initial milestone in a specific research program.

As a result, FIMECS will receive 200 million yen from Astellas, which will be recorded as business revenue for the second quarter of the fiscal year ending December 31, 2024. In the future research and development of this program, each company will accelerate the discovery of development candidates by further optimization efforts by FIMECS and combination with technology provided by Astellas. If a development candidate is identified and leads to the commercialization of a new pharmaceutical product, FIMECS may receive exceeding 15 billion yen based on the progress of development, regulatory, and sales milestones, as well as royalties in the single-digit percentage range of product sales.

The impact of this matter on the consolidated financial results for the fiscal year ending December 31, 2024, has already been incorporated in the consolidated financial forecast of RaQualia for the current fiscal year disclosed on February 14, 2024. On March 26, 2024, RaQualia made FIMECS a wholly-owned subsidiary through a share acquisition. This milestone achievement is a memorable first step after FIMECS joined the RaQualia Group, and we believe that this matter will significantly contribute to the RaQualia Group’s growth potential and corporate value in the medium to long term.

###

RaQualia Pharma, Inc. Media Contact:

RaQualia Pharma, Inc.

8F Meieki Southside Square, 1-21-19 Meieki Minami Nakamura-ku, Nagoya 450-0003, Japan

Tel: +81-446-6100

Email: ask@raqualia.com